A study evaluating prognostic ability of cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumours.

Trial Profile

A study evaluating prognostic ability of cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumours.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2016 New trial record
    • 11 Oct 2016 Results assessing prognostic role of CD and DI of everolimus for patients with pancreatic neuroendocrine tumours presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top